In the largest human study conducted to date, subjects taking a proprietary extract of the white bean, PhaseLite (Phase 2 Carb Controller®) lost significantly more weight than those on placebo after 12 weeks. In addition, 73.5 percent of the participants in the weight management phase successfully maintained their body weight after 24 weeks.
According to lead researcher Barbara Grube, MD, the weight management study was the longest-duration single clinical study conducted on the proprietary extract, and the first to show benefits for weight management. Study results were published in the journal Obesity.
“We also discovered other secondary efficacy parameters,” said Grube. “For instance, after 12 weeks, the active group lost significantly more body fat mass and waist circumference compared to the placebo group.”
“From this data, we conclude that the reduction in body weight was due to the loss of fat mass, instead of muscles,” added Grube. “Improvement in body composition was also shown in the significant reduction in waist measurement in the active group compared to the placebo group.”
Mathias Miller, chief scientific officer, InQpharm, manufacturer of PhaseLite, said the subjects also completed the “Control of Eating Questionnaire” (COEQ), which uses visual analogue scales to assess subject’s feelings such as hunger, satiety and food cravings.
“After 12 weeks, the active arm in the weight-loss study experienced a statistically significant decrease in their desire as well as in their frequency and strength of food cravings for chocolates and other sweet foods, whereas the placebo group experienced a significant increase in the difficulty in resisting particular types of food,” said Miller.
Mitch Skop, senior director of new product development, Pharmachem Laboratories, developer of Phase 2 Carb Controller, said “These findings confirm that Phase 2 not only reduces the absorption of calories from carbohydrates, but also helps to reduce food cravings for sweet foods and chocolates. This contributes greatly to the success of the weight loss regimen, as well as a happy and alert lifestyle.”
In the double-blind weight loss phase, 123 subjects were randomized to receive either the bean extract or placebo. All subjects adhered to a mildly hypocaloric diet. Body weight and other body composition parameters were measured at baseline and every four weeks thereafter. During the single arm, open label weight management trial, energy intake of the 49 subjects was not controlled. Efficacy parameters were measured at baseline, week 12 and week 24.
The studies were conducted in Berlin, Germany, and performed with the recommendations of the European Food Safety Authority. The research was supported by InQpharm Group, a global developer and marketer of unique, safe, natural compounds that have therapeutic properties in human and animal markets.